Equities Analysts Offer Predictions for KYMR Q1 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Equities research analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Kymera Therapeutics in a research note issued on Monday, March 3rd. B. Riley analyst K. Patel anticipates that the company will post earnings of ($0.94) per share for the quarter. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($1.09) EPS and Q4 2025 earnings at ($1.09) EPS.

A number of other research firms have also issued reports on KYMR. HC Wainwright raised their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. BTIG Research assumed coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target on the stock. BMO Capital Markets assumed coverage on Kymera Therapeutics in a report on Friday, December 6th. They set a “market perform” rating and a $55.00 price target on the stock. Morgan Stanley raised their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 6th. Finally, Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $38.00 to $57.00 in a report on Monday, December 2nd. Three research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.69.

Kymera Therapeutics Stock Performance

KYMR opened at $30.68 on Tuesday. The business’s 50-day simple moving average is $38.60 and its 200-day simple moving average is $43.56. Kymera Therapeutics has a one year low of $29.07 and a one year high of $53.27. The stock has a market capitalization of $1.99 billion, a P/E ratio of -13.11 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Blue Trust Inc. lifted its position in shares of Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after acquiring an additional 270 shares during the period. State of Wyoming acquired a new position in shares of Kymera Therapeutics during the 4th quarter worth approximately $45,000. GF Fund Management CO. LTD. acquired a new position in shares of Kymera Therapeutics during the 4th quarter worth approximately $55,000. KBC Group NV raised its position in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Kymera Therapeutics during the 3rd quarter worth approximately $95,000.

Insider Buying and Selling at Kymera Therapeutics

In other news, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ellen Chiniara sold 2,241 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the sale, the insider now owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,788 shares of company stock valued at $455,202. 15.82% of the stock is owned by corporate insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.